Results from the Danish SORT-OUT II study, the largest randomized trial to date comparing Taxus and Cypher drug-eluting ...

A large California-based study has shown that patients with heart failure who start taking statins, compared with those who don't, will live longer and have a lower hospitalization risk regardless of cholesterol levels, presence or absence of coronary disease, and other CV drug therapies, “Heartwire” reported this week.

Agfa HealthCare has signed a multi-million dollar deal with Thomas Memorial Hospital in South Charleston, WV and will ...

British researchers have concluded that counseling and education aimed at preventing coronary heart disease have no impact on mortality and little effect in terms of clinical events, reports “heartwire.” Dr Shah Ebrahim (London School of Tropical Medicine, UK) and colleagues report their findings in the Oct. 18, 2006 Cochrane Database of Systematic Reviews.

Early clinical results from Abbott's ongoing ABSORB clinical trial, the world's first study to evaluate the safety and performance of a fully bioabsorbable drug-eluting stent platform for the treatment of coronary artery disease in humans, were presented during the 18th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.

GlaxoSmithKline and Flamel Technologies announced FDA approval of once-a-day Coreg CR (carvedilol phosphate) extended ...

A stent designed to dissolve after it completes its task of propping open narrowed heart arteries is being tested by scientists. The first human experiment with the dissolving stent is being conducted with 26 patients at hospitals in New Zealand and Europe, the Associated Press reported. The study is designed to test whether the stent is safe enough to be used in larger studies.

A new program designed to provide hospitals with practical tools to help them reduce door-to-balloon times in STEMI ...